Radiolabeled Antibodies Against Müllerian-Inhibiting Substance Receptor, Type II: New Tools for a Theranostic Approach in Ovarian Cancer-Reference-Cited by-同舟云学术

Radiolabeled Antibodies Against Müllerian-Inhibiting Substance Receptor, Type II: New Tools for a Theranostic Approach in Ovarian Cancer

Published:2018-04-19 Issue:8 Volume:59 Page:1234-1242
ISSN:0161-5505
Container-title:Journal of Nuclear Medicine
language:en
Short-container-title:J Nucl Med

Author:

Deshayes Emmanuel,Ladjohounlou Riad,Le Fur Pierre,Pichard Alexandre,Lozza Catherine,Boudousq Vincent,Sevestre Samuel,Jarlier Marta,Kashani Roxana,Koch Joanna,Sosabowski Jane,Foster Julie,Chouin Nicolas,Bruchertseifer Frank,Morgenstern Alfred,Kotzki Pierre-Olivier,Navarro-Teulon Isabelle,Pouget Jean-Pierre

Publisher

Society of Nuclear Medicine

Subject

Radiology Nuclear Medicine and imaging

Reference47 articles.

1. Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012

2. Jaaback K Johnson N Lawrie TA . Intraperitoneal chemotherapy for the initial management of primary epithelial ovarian cancer. Cochrane Database Syst Rev. 2016;CD005340.

3. Rationale for integrating early postoperative intraperitoneal chemotherapy into the surgical treatment of gastrointestinal cancer;Sugarbaker;Semin Oncol.,1989

4. Hyperthermic intraperitoneal chemotherapy (HIPEC) and cytoreductive surgery (CRS) in ovarian cancer: A systematic review and meta-analysis

Cited by 14 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Development of an in vivo ovarian cancer peritoneal carcinomatosis model for radioimmunotherapy testing;Methods in Cell Biology;2024

2. Gadolinium-Based Nanoparticles Sensitize Ovarian Peritoneal Carcinomatosis to Targeted Radionuclide Therapy;Journal of Nuclear Medicine;2023-10-19

3. Astatine-211 based radionuclide therapy: Current clinical trial landscape;Frontiers in Medicine;2023-01-06

4. Folate-based radiotracers for nuclear imaging and radionuclide therapy;Coordination Chemistry Reviews;2022-11

5. Radiolabeled Antibodies for Cancer Radioimmunotherapy;Nuclear Medicine and Immunology;2021-11-25